Trial Information

Differences in SELDI Produced Serum Protein Profiles of Non-small Cell Lung Cancer Patients Compared to Healthy Heavy Smoking Adults

A prospective longitudinal patient-based pilot study is proposed whereby surfaced enhanced
laser desorption ionization time-of-flight mass spectroscopy (SELDI-TOF-MS) will be used to
discover and validate serum proteomic expression profiles diagnostic of early lung cancer. A
unique approach will be used to compare the serum proteomic expression profiles of patients
with non-small cell lung cancer compared to healthy heavy smoking adults, as well as
differences before and after anatomic pulmonary resection with curative intent.
Discriminatory proteins will be selected by their differential expression before compared to
after surgical removal of a tumor. The protein profile of blood obtained from the draining
pulmonary vein at the time of resection will be used to identify materials potentially shed
by the tumor that may serve as biomarkers in peripheral blood. The serum samples will be
used to develop a training data set and then a test set for validation using a class
prediction model. Candidate proteomic patterns will then serve as a basis for a larger
prospective multi-centre clinical trial.